Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial.

J Natl Cancer Inst · 2014 · PMC3906991 · PMID 24317176

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

After the reporting of the 50% survival data, which showed a trend in favor of 500mg over 250mg, it was agreed to perform a final survival analysis after 75% of patients had died.

also in 33,225 other papers

a numerical trendno p-value reported

The OS analysis suggested a numerical trend in favor of 500mg over 250mg despite the lack of a statistically significant difference ( 9 ).

also in 723 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.